95
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Meconium-stained amniotic fluid: a risk factor for postpartum hemorrhage

, , , , , & show all
Pages 1671-1675 | Published online: 11 Sep 2018

Abstract

Background/aim

Clinical data with respect to the impact of meconium on the risk of maternal hemorrhage are scarce. Therefore, in this study, we aimed to determine whether meconium-stained amniotic fluid (MSAF) represents a risk factor for postpartum hemorrhage (PPH) after vaginal delivery in a large unselected population.

Patients and methods

A retrospective cohort study evaluated 78,542 consecutive women who had a vaginal delivery between 24th and 44th weeks of gestation. The women who had undergone cesarean section were excluded to avoid possible bias. Postpartum blood loss was measured with graduated blood sack. Postpartum blood loss between 1,000 and 2,000 mL and >2,000 mL were classified as moderate and severe PPH, respectively.

Results

A total of 74,144 patients were available for analysis. According to the color of amniotic fluid (AF), two groups of patients were identified: MSAF (n=10,997) and clear AF (n=63,147). The rates of severe and massive PPH were found to be significantly higher in the MSAF group than that of clear AF group (OR=1.3, 95% CI: 1.2–1.5, p<0.001 and OR=2.5, 95% CI: 1.5–4.2, p<0.001). Operative vaginal delivery rate was found to be higher in the MSAF group than that of clear AF group, but the difference was only borderline significant (OR=1.5, 95% CI: 1.0–2.2, p=0.05). There were no significant differences between the MSAF and the clear AF groups with respect to episiotomies, second- or third-degree perineal tears, vaginal–perineal thrombus, cervical lacerations, vaginal births after cesarean section, twin deliveries, and placental retention rates.

Conclusion

To the best of our knowledge, this is the first clinical study that has investigated the role of MSAF as a risk factor for PPH after vaginal delivery in an unselected population. Our results suggest that MSAF is significantly associated with higher risk of moderate and severe PPH than clear AF.

Introduction

Postpartum hemorrhage (PPH) is one of the leading causes of maternal mortality.Citation1 Several recent population-based studies have observed an increasing trend in the incidence of PPH over time.Citation2,Citation3 Several factors, such as maternal age, obesity, grand multiparity, uterine fibroids, previous cesarean delivery, multiple pregnancy, placenta previa or abruption, preeclampsia/eclampsia, amnionitis, fetal macrosomia, labor induction, instrumental vaginal delivery, cesarean delivery, cervical laceration, and uterine rupture have been associated with high risk of major PPH.Citation3Citation8 Moreover, recently, new risk factors have been identified, including index of multiple deprivation (education, skills, and training), multiparity without cesarean section, and antenatal administration of steroids.Citation9

Amniotic fluid (AF) contains many coagulation factors which exert procoagulant, anticoagulant, and fibrinolytic activities.Citation10Citation19 A thrombogenic role of amniotic cells has also been well documented.Citation20 In an animal model, it has been shown that the infusion of AF causes activation of coagulation.Citation21 This effect was significantly more pronounced by injecting AF contaminated with meconium.Citation21

Unfortunately, there are scant clinical data on the impact of meconium on the risk of maternal hemorrhage. The only published study found no significant differences in the rate of hemorrhage between the patients with meconium-stained amniotic fluid (MSAF) and clear AF.Citation22 However, only patients with preterm delivery were included. Moreover, a very low rate of PPH (<0.6%) was observed.Citation22

In this study, we aimed to determine whether MSAF represents a risk factor for PPH after vaginal delivery in a large unselected population.

Patients and methods

The study population consisted of 78,542 consecutive women who had a vaginal delivery at IRCCS Burlo Garofolo, Trieste, Italy, from May 1972 to December 2013, between 24th and 44th weeks of gestation. Data were collected from the delivery room records.

The women who had undergone cesarean section were excluded to avoid possible bias. As a matter of fact, blood loss during the cesarean section can be estimated only with wide approximation.Citation23 In addition, these cases have a high risk of hemorrhage due to surgeryCitation3 and the incidence of stained AF could have been much higher, given the significant number of fetal distress as indication for cesarean section.Citation24 Finally, the site of entry of AF is through beant venous vessels in placental site and through venous vessels in delivery channel that get lacerated by fetal passage; therefore, we excluded the potential passage through hysterotomic wound that happens in cesarean section. We collected data regarding the color of AF and postdelivery blood loss. According to the color of AF, two groups of patients were identified: MSAF and clear AF. MSAF includes any meconium: fresh, old, thick (dark green in color and of pea soup consistency with particulate matter), or thin (lightly stained yellow or greenish color).Citation25,Citation26

In all patients, postpartum blood loss was measured with graduated blood sack. Postpartum blood losses were measured using graduated blood drape consistently over the entire 41 years. The drape was placed under the buttocks of the woman immediately after delivery and drainage of the AF. Blood loss was assessed for at least 1 hour after delivery of the baby. Whenever persistent bleeding occurred, blood loss was measured until active bleeding stopped.Citation27,Citation28

PPH was defined as a cumulative postpartum blood loss ≥1,000 mL according to the American College of Obstetricians and Gynecologists (ACOG) nomenclature consensus conference (reVITALize).Citation29 Postpartum blood loss between 1,000 and 2,000 mL and >2,000 mL were classified as moderate and severe PPH, respectively.

Chi-square test and Fisher’s exact test, when appropriate, were used to examine the relationship between the presence of MSAF and categorical parameters. OR and 95% CIs were calculated. A p-value <0.05 was considered statistically significant. Statistical analysis was performed using GraphPad Prism version 6 (GraphPad Software, Inc., La Jolla, CA, USA).

The study was approved by the Ethical Committee of IRCCS Burlo Garofolo, Trieste, on April 14th 2015 with protocol Number 759/2015. It was not necessary to obtain informed consent in this study as the regulatory standards in Italy do not require consent for a retrospective study; patients’ data were treated with extreme confidentiality for strictly scientific purposes.

Results

A total of 78,452 deliveries were evaluated. In about 2.5% of the cases, blood loss was considered, but the color of AF was not described. In 0.1% of the cases, AF was absent or not reported. In about 3% of the cases, blood loss was not reported. Finally, data of a total of 74,144 patients were available for analysis.

There were 10,997 cases (14.8%) with MSAF and 63,147 cases (85.2%) with clear AF. The rates of moderate PPH (blood loss between 1,000 and 2,000 mL) and severe PPH (blood loss >2,000 mL) were found to be significantly higher in the MSAF group than that of clear AF group (). MSAF was found to be significantly associated with high risk of moderate PPH (OR=1.3, 95% CI: 1.2–1.5) and severe PPH (OR=2.5, 95% CI: 1.4–4.2) (). The operative vaginal deliveries with vacuum or forceps were higher in the MSAF group than that of clear AF group, but the difference was only borderline significant (OR=1.5, 95% CI: 1.0–2.2, p=0.05). There were no statistically significant differences between the clear AF group and the MSAF group regarding episiotomies, second- or third-degree perineal tears, vaginal–perineal thrombus, cervical lacerations, vaginal births after cesarean section, twin deliveries, and placental retention requiring manual placental removal.

Table 1 Postpartum blood loss in meconium-stained amniotic fluid (MSAF) and clear amniotic fluid (AF) group

Discussion

In this study, we examined a very large population of women who had vaginal delivery. We collected data regarding the color of AF and postdelivery blood loss. The incidence of deliveries with MSAF was found to be 14.8%, which is slightly higher than what is reported by the other authors.Citation30Citation32 However, it may be influenced by the fact that between 1972 and 2004, delivery management was to wait, in most cases, for spontaneous labor till the 42nd week. Several studies have reported that MSAF proportionally increases with the increase of gestational age.Citation24,Citation33,Citation34 We observed a significant increase in the risk of moderate and severe PPH in the presence of MSAF. Our results do not agree with those of the other clinical studies published so far. Mazor et alCitation22 found that MSAF was not a risk factor for PPH. However, it should be noticed that this study included only preterm delivery and that a very low rate of PPH was reported.Citation22

We are unable to explain why meconium may increase the risk of hemorrhage. The coagulation and fibrinolysis in AF have been extensively investigated. Most proteins of the coagulation and fibrinolysis system, and many vasoactive and procoagulant substances, such as platelet activating factor, cytokines, bradykinin, thromboxane, leukotrienes, and arachidonic acid have been detected in AF.Citation10Citation19

However, data regarding the effects of MSAF on coagulation and fibrinolysis system are scarce; there is no such data with respect to human beings, and there are only few animal studies on this topic. Petroianu et alCitation21 showed that the infusion of native AF (including meconium) triggered a response similar to disseminated intravascular coagulation (DIC). After infusion of centrifuged AF (excluding meconium), in spite of the much higher volumes used, the changes were less pronounced. The authors concluded that the factor (or factors) initiating DIC after infusion of native AF are unknown and are probably contained in meconium, since meconium-free AF is not life-threatening even if very high volumes are infused.Citation21 Similar results have been obtained in pregnant goats where left ventricular dysfunction and dysoxia were observed only with the infusion of AF containing meconium.Citation35

Recently, it has been observed that the injection of autologous AF induced a transient and severe thrombocytopenia, but not AF embolism in a rabbit model.Citation35 However, thromboelastographic analysis indicated that AF could initiate the cascade of coagulation. The authors concluded that other factors such as the presence of meconium in AF may be needed to provoke more severe clinical signs.Citation36 Since AF cannot be absorbed through vaginal mucosa, it can be hypothesized that coagulopathy and subsequent hemorrhage are caused by the entrance of AF into maternal circulation. It has been reported that this event is frequent,Citation37 and several cases of AF embolism with isolated coagulopathy have been reported.Citation38Citation44 If AF is contaminated by meconium, the severity of coagulopathy and hemorrhage might significantly increase. In fact, we have observed that in patients with MSAF, the rates, both of moderate and severe hemorrhages were significantly higher than that of clear AF group.

In this study, we found a higher, although not significant, incidence of MSAF in operative deliveries than that of other studies.Citation45Citation47 This may be due to higher incidence of fetal hypoxia in these cases involving a higher risk of meconium release during the labor.Citation47 Several other hypotheses have been suggested to explain this finding. Meconium has been associated with fetal heart rate abnormalitiesCitation48 that may induce physicians to an aggressive obstetric management. The presence of meconium per se may cause physician concern for fetal well-being thus lowering the threshold for intervention.Citation46 Meconium might negatively influence the regular labor progression, perhaps through subclinical infection.Citation46 Experimental studies showed that meconium may inhibit the umbilical vessel smooth muscle contractile effect of a thromboxane A2 analog.Citation49 Finally, it is possible that meconium inhibits uterine smooth muscle contraction and increases the risk of labor dystocia and operative delivery.Citation46

This study has some advantages. To the best of our knowledge, this is the first clinical, specifically addressed study that has investigated the role of MASF as risk factor for PPH in an unselected population of pregnant women. It is a single center study and it included data from a very large number of deliveries, thus reducing the role of potential confounding factors. The study also has some limitations. It is, in fact, a retrospective study over a long span of time and assessment of AF characteristics was eye-based, which may include bias due to subjective evaluation. Moreover, data were collected from the delivery room records and some information regarding antenatal complications of pregnancy were lacking.

Conclusion

Our results suggest that MSAF is significantly associated with higher risk of moderate and severe PPH than clear AF. Therefore, in case of MASF, more attention should be paid to postpartum bleeding. Further studies are needed to clarify the mechanism by which meconium increases the risk of hemorrhage.

Disclosure

The authors report no conflicts of interest in this work.

References

  • SheldonWRBlumJVogelJPSouzaJPGülmezogluAMWinikoffBWHO Multicountry Survey on Maternal and Newborn Health Research Network Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn HealthBJOG2014121Suppl 151324641530
  • KnightMCallaghanWMBergCTrends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative GroupBMC Pregnancy Childbirth200995519943928
  • KramerMSBergCAbenhaimHIncidence, risk factors, and temporal trends in severe post-partum hemorrhageAm J Obstet Gynecol20132095449.e1449.e723871950
  • NgwenyaSPostpartum hemorrhage: incidence, risk factors, and outcomes in a low-resource settingInt J Womens Health2016864765027843354
  • KhireddineILe RayCDupontCRudigozRCBouvier-ColleMHDeneux-TharauxCInduction of labor and risk of postpartum hemorrhage in low risk parturientsPLoS One201381e5485823382990
  • GollopNDChildsCACoupeBMacFarlaneSBurrellJKumarBBody weight, body image and primary postpartum haemorrhage: a review of the literatureJ Obstet Gynaecol201434537338224694033
  • SentilhesLMerlotBMadarHSztarkFBrunSDeneux-TharauxCPostpartum haemorrhage: prevention and treatmentExpert Rev Hematol20169111043106127701915
  • MillerCMCohnSAkdagliSCarvalhoBBlumenfeldYJButwickAJPostpartum hemorrhage following vaginal delivery: risk factors and maternal outcomesJ Perinatol201737324324827977018
  • BrileyASeedPTTydemanGReporting errors, incidence and risk factors for postpartum haemorrhage and progression to severe PPH: a prospective observational studyBJOG2014121787688824517180
  • WeinerAEReidDEThe pathogenesis of amniotic fluid embolism. III. Coagulant activity of amniotic fluidN Engl J Med19502431659759814780342
  • PhilipsLLDavidsonECJrProcoagulant properties of amniotic fluidAm J Obstet Gynecol197211379119194635740
  • OmsjøIHØianPMaltauJMØsterudBThromboplastin activity in amniotic fluidGynecol Obstet Invest1985191153988141
  • EstellésAGilabertJAndrésCEspañaFAznarJPlasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancyThromb Haemost19906422812852125378
  • LockwoodCJBachRGuhaAZhouXMillerWANemersonYAmniotic fluid contains tissue factor, a potent initiator of coagulationAm J Obstet Gynecol19911655 Pt 1133513411957857
  • SarigGKlil-DroriAJChap-MarshakDBrennerBDruganAActivation of coagulation in amniotic fluid during normal human pregnancyThromb Res2011128549049521504838
  • UszyńskiMUszyńskiWCoagulation and fibrinolysis in amniotic fluid: physiology and observation on amniotic fluid embolism, preterm fetal membrane rupture, and pre-eclampsiaSemin Thromb Hemost201137216517421370219
  • UszyńskiWZekanowskaEUszyńskiMZylińskiAKuczyńskiJNew observations on procoagulant properties of amniotic fluid: microparticles (MPs) and tissue factor-bearing MPs (MPs-TF), comparison with maternal blood plasmaThromb Res2013132675776024157083
  • LiuSWeiLZhangYXuMWangCZhouJProcoagulant activity and cellular origin of microparticles in human amniotic fluidThromb Res2014133464565124439679
  • UszyńskiWŻekanowskaEUszyńskiMKieszkowskiPActivation contact system (ACS) and tissue factor (TF) in human amniotic fluid: measurements of ACS components and TF, and some implications on the pathophysiology of amniotic fluid embolismThromb Res2015135469970225669600
  • ZhouJLiuSMaMProcoagulant activity and phosphatidylserine of amniotic fluid cellsThromb Haemost2009101584585119404537
  • PetroianuGAAltmannsbergerSHMaleckWHMeconium and amniotic fluid embolism; effects on coagulation in pregnant minipigsCrit Care Med199927234835510075060
  • MazorMHershkovitzRBashiriAMeconium stained amniotic fluid in preterm delivery is an independent risk factor for perinatal complicationsEur J Obstet Gynecol Reprod Biol19988119139846706
  • GluckOMizrachiYKovoMDivonMBarJWeinerEMajor underestimation and overestimation of visual blood loss during cesarean deliveries: can they be predicted?Arch Gynecol Obstet2017296590791328879437
  • HierschLKrispinEAviramAWiznitzerAYogevYAshwalEEffect of meconium-stained amniotic fluid on perinatal complications in low-risk pregnancies at termAm J Perinatol201633437838426479168
  • CialonePRShererDMRyanRMSinkinRAAbramowiczJSAmnio-infusion during labor complicated by particulate meconium-stained amniotic fluid decreases neonatal morbidityAm J Obstet Gynecol199417038428498141214
  • BhatRYRaoAMeconium-stained amniotic fluid and meconium aspiration syndrome: a prospective studyAnn Trop Paediatr200828319920318727848
  • PatelAGoudarSSGellerSEDrape estimation vs. visual assessment for estimating postpartum hemorrhageInt J Gynaecol Obstet200693322022416626718
  • AmbardekarSShochetTBrackenHCoyajiKWinikoffBCalibrated delivery drape versus indirect gravimetric technique for the measurement of blood loss after delivery: a randomized trialBMC Pregnancy Childbirth20141427625128176
  • American College of Obstetricians and GynecologistsreVITALize obstetric data definitions Available from: http://www.acog.org/-/media/Departments/Patient-Safety-and-Quality-Improvement/2014reVITALizeObstetricDataDefinitionsV10.pdfAccessed July 25, 2018
  • KhazardoostSHantoushzadehSKhooshidehMBornaSRisk factors for meconium aspiration in meconium stained amniotic fluidJ Obstet Gynaecol200727657757917896254
  • WalshMCFanaroffJMMeconium stained fluid: approach to the mother and the babyClin Perinatol200734465366518063111
  • BhatRVidyasagarDDelivery room management of meconium-stained infantClin Perinatol201239481783123164180
  • FischerCRybakowskiCFerdynusCSagotPGouyonJBA population-based study of meconium aspiration syndrome in neonates born between 37 and 43 weeks of gestationInt J Pediatr2012201232154522187569
  • HierschLKrispinELinderNMeconium-stained amniotic fluid and neonatal morbidity in low-risk pregnancies at term: the effect of gestational ageAm J Perinatol201734218319027367282
  • HankinsGDSnyderRRClarkSLSchwartzLPattersonWRButzinCAAcute haemodynamic and respiratory effects of amniotic fluid embolism in the pregnant goat modelAm J Obstet Gynecol19931684111311308475957
  • RannouBRivardGEGainsMJBédardCIntravenous injection of autologous amniotic fluid induces transient thrombocytopenia in a gravid rabbit model of amniotic fluid embolismVet Clin Pathol201140452452922092306
  • ShamshirsazAAClarkSLAmniotic fluid embolismObstet Gynecol Clin North Am201643477979027816160
  • PorterTFClarkSLDildyGAHankinsGDVIsolated disseminated intravascular coagulation and amniotic fluid embolismAm J Obstet Gynecol1996174486
  • DaviesSAmniotic fluid embolism and isolated disseminated intravascular coagulationCan J Anaesth1999465 Pt 145645910349924
  • AwadITShortenGDAmniotic fluid embolism and isolated coagulopathy: atypical presentation of amniotic fluid embolismEur J Anaesthesiol200118641041311412296
  • LevyRFurmanBHagayZJFetal bradycardia and disseminated coagulopathy: atypical presentation of amniotic fluid embolismActa Anaesthesiol Scand20044891214121515352972
  • YangJIKimHSChangKHRyuHSJooHJAmniotic fluid embolism with isolated coagulopathy: a case reportJ Reprod Med2006511646616482780
  • MatsuzawaYFurukawaSKiyomotoCFujiwaraMMochizukiMDifferent clinical courses with severe postpartum coagulopathy in two cases showing the same histological findings those local amniotic fluid emboliJ Syndromes201634
  • LiaoCYLuoFJAmniotic fluid embolism with isolated coagulopathy: a report of two casesJ Clin Diagn Res20161010QD03QD05
  • MaymonEChaimWFurmanBGhezziFShoham VardiIMazorMMeconium stained amniotic fluid in very low risk pregnancies at term gestationEur J Obstet Gynecol Reprod Biol19988021691739846662
  • TranSHCaugheyABMusciTJMeconium-stained amniotic fluid is associated with puerperal infectionsAm J Obstet Gynecol2003189374675014526306
  • BeckerSSolomayerEDoganCWallwienerDFehmTMeconium-stained amniotic fluid – perinatal outcome and obstetrical management in a low-risk suburban populationEur J Obstet Gynecol Reprod Biol20071321465016837118
  • NathanLLevenoKJCarmodyTJ3rdKellyMAShermanMLMeconium: a 1990s perspective on an old obstetric hazardObstet Gynecol19948333293328127520
  • MontgomeryLDBelfortMASaadeGRMoiseKJJrVedernikovYPMeconium inhibits the contraction of umbilical vessels induced by the thromboxane A2 analog U46619Am J Obstet Gynecol19951734107510787485296